Free tool
FAERS Monitor: Lymphir
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761312 or its brand name (Lymphir, Denileukin Diftitox-Cxdl). Reports on generic versions are filed under their own applications.
Reports
10
Serious
8
80% of reports
Hospitalization
5
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- capillary leak syndrome3
- hypoxia2
- sepsis2
- acute kidney injury1
- atrial fibrillation1
- blood albumin decreased1
- cognitive disorder1
- communication disorder1
- condition aggravated1
- death1
- disease progression1
- enterovirus infection1
- failure to thrive1
- hepatic enzyme increased1
- hypophagia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 9 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| capillary leak syndromeSignal | 3 | 3057.2 | 1185.0 | 6,356 |
| enterovirus infection | 1 | 2439.6 | 379.6 | 608 |
| communication disorder | 1 | 550.1 | 85.7 | 137 |
| failure to thrive | 1 | 405.4 | 63.1 | 100 |
| blood albumin decreased | 1 | 265.2 | 41.3 | 65 |
| hypoxia | 2 | 119.5 | 34.6 | 132 |
| hypophagia | 1 | 82.3 | 12.8 | 20 |
| cognitive disorder | 1 | 45.0 | 7.0 | 10 |
| sepsis | 2 | 37.7 | 10.9 | 40 |
| hepatic enzyme increased | 1 | 30.9 | 4.8 | 7 |
| atrial fibrillation | 1 | 21.6 | 3.4 | 4 |
| disease progression | 1 | 17.8 | 2.8 | 4 |
| acute kidney injury | 1 | 13.7 | 2.1 | 3 |
| condition aggravated | 1 | 6.9 | 1.1 | 1 |
| death | 1 | 2.4 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.